ArticleJournal of translational medicine2025
Gut microbiota dysbiosis exacerbates heart failure by the LPS-TLR4/NF-κB signalling axis: mechanistic insights and therapeutic potential of TLR4 inhibition.
Article in Journal of translational medicine, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. Cited by 19 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
19 citing papers in PubMed.
- Dietary Matcha Attenuates High-Fat High-Sugar Diet-Induced Cardiomyocyte Hypertrophy in Association with Gut Microbiota Remodeling in Mice.Nutrients · 2026Article
- Lactobacillus rhamnosus and Saccharomyces boulardii Attenuate LPS-Induced Cognitive and Affective Dysfunction Associated with Hippocampal Neuroinflammatory and Neurochemical Alterations : Probiotics Mitigate LPS-Induced Neuroinflammation and Cognitive Deficits.Neurochemical research · 2026Article
- ADAM and ADAMTS proteases as integrative hubs in heart failure pathogenesis and therapy.iScience · 2026Review
- Review
- Exploratory analysis of gut microbiota and its association with peripheral blood immune cell populations in canine myxomatous mitral valve disease.BMC veterinary research · 2026Article
- Gut commensal Odoribacter splanchnicus attenuates hyperlipidemic periodontitis via gut-oral metabolic transmission of β-GPA.NPJ biofilms and microbiomes · 2026Article
- Gut Microbiome Dysbiosis in Metabolic Syndrome: Current Evidence and Emerging Perspectives.Nutrients · 2026Review
- Sodium Butyrate Attenuates Isoprenaline-Induced Myocardial Injury via Restoring the Gut-Heart Axis and Suppressing TLR4/NF-κB Signaling.Current issues in molecular biology · 2026Article
- Modulation of the gut-heart axis by exercise in diabetic cardiomyopathy: Microbial mechanisms and clinical implications.iScience · 2026Review
- Live tissue microbiota and bacterial translocation: mechanisms and translational perspectives in cardiometabolic diseases.Reviews in endocrine & metabolic disorders · 2026Review
- MEKK3 bridges gut-brain communication and cerebral cavernous malformation pathogenesis.Cell death discovery · 2026Review
- Baicalin ameliorates interstitial cystitis/bladder pain syndrome by inhibiting the TLR4/NF-κB pathway.Naunyn-Schmiedeberg's archives of pharmacology · 2026Article
- The gut-heart axis in heart failure: from bidirectional pathophysiological mechanisms to integrative therapeutic strategies.Frontiers in microbiology · 2026Review
- The Gut Microbiota-NLRP3 Inflammasome Axis in Chronic Heart Failure: Mechanisms Across Heart Failure Phenotypes and Therapeutic Perspectives.Journal of inflammation research · 2026Review
- Gut-heart axis disruption and LPS translocation: driving atrial fibrillation through inflammatory storm and fibrotic mechanisms.Frontiers in endocrinology · 2026Review
- Host-gut microbiota interactions in health and disease: mechanisms and intervention strategies.Frontiers in microbiology · 2026Review
- Heart Failure and Cognitive Impairment Through the Lens of the Gut Microbiome: A Narrative Review.Journal of personalized medicine · 2025Review
- The gut-placenta axis in preeclampsia: unraveling the regulatory network and clinical prospects in pathogenesis.Frontiers in cellular and infection microbiology · 2025Review
- Gut Microbiome and Cardiovascular Health: Mechanisms, Therapeutic Potential and Future Directions.Heart international · 2025Review
Corrections and comments
- Erratum issued
Authors and funding
12 authors.
Funding
Abstract
objectiveThis study aimed to investigate the associations between gut microbiota dysbiosis and alterations in cardiac function and to elucidate the underlying molecular mechanisms involved.
methodsEighteen rats were divided into a control group (n = 6), a heart failure (HF) group (n = 6), and a TAK-242 intervention group (n = 6). Cardiac function was assessed using small-animal echocardiography. Serum levels of brain natriuretic peptide (BNP) and inflammatory cytokines were measured by ELISA. Western blotting was used to detect phosphorylated p65 (P-p65) protein expression in myocardial tissue, and 16 S rRNA sequencing was performed to analyse the composition of the faecal gut microbiota.
resultsCompared with the control group, the heart failure group presented significant gut microbiota dysbiosis, characterized by increased relative abundance of Bacteroidetes and Spirochaetes and decreased relative abundance of Actinobacteria and Proteobacteria, along with reduced species diversity. The serum levels of lipopolysaccharide (LPS), IL-1β, IL-17, IL-6, and TNF-α were significantly elevated (P < 0.05). Myocardial tissue pathology revealed disordered myocardial fibre arrangement and significant lymphocyte infiltration. TAK-242 intervention normalized the gut microbiota composition; reduced LPS and inflammatory cytokine levels; improved the left ventricular ejection fraction (LVEF) and left ventricular fractional shortening (LVFS); and decreased the left ventricular end-systolic diameter (LVESD), left ventricular end-diastolic diameter (LVEDD), and BNP levels. Myocardial tissue pathology also improved. Western blot analysis revealed increased TLR4 、P-IKBα/ IKBα and P-p65/p65 expressions in the heart failure group, which were significantly inhibited by TAK-242 (P < 0.05).
conclusionGut microbiota dysbiosis exacerbates heart failure by activating myocardial inflammation through the LPS-TLR4/NF-κB signalling pathway. By modulating this pathway, TAK-242 improves cardiac function, suggesting its potential as a therapeutic target for heart failure. CLINICAL TRIAL NUMBER: Not applicable.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.